[
  {
    "ts": "2026-01-21T12:10:54+00:00",
    "headline": "Merck & Co (MRK) to Generate $70 Billion in Revenue from Emerging Businesses By Mid-2030s",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the best undervalued wide moat stocks. With competition rising to the company’s cancer therapy Keytruda, Merck & Co., Inc. (NYSE:MRK) is setting itself up for long-term growth. On January 12, 2026, the company raised its outlook for new growth drivers. Accordingly, Merck projects $70 billion in revenue […]",
    "url": "https://finance.yahoo.com/news/merck-co-mrk-generate-70-121054424.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "d0985755-b7b4-3dca-bccf-9f65ada2d98f",
      "content": {
        "id": "d0985755-b7b4-3dca-bccf-9f65ada2d98f",
        "contentType": "STORY",
        "title": "Merck & Co (MRK) to Generate $70 Billion in Revenue from Emerging Businesses By Mid-2030s",
        "description": "",
        "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the best undervalued wide moat stocks. With competition rising to the company’s cancer therapy Keytruda, Merck & Co., Inc. (NYSE:MRK) is setting itself up for long-term growth. On January 12, 2026, the company raised its outlook for new growth drivers. Accordingly, Merck projects $70 billion in revenue […]",
        "pubDate": "2026-01-21T12:10:54Z",
        "displayTime": "2026-01-21T12:10:54Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/2599eaa3ebd7014f60b50968b758cbd7",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Merck & Co (MRK) to Generate $70 Billion in Revenue from Emerging Businesses By Mid-2030s ",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6RdHqnIaUyPg6ymCeQ_LNA--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/2599eaa3ebd7014f60b50968b758cbd7.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fJfT7.tyQe1oBafYUeZwEA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/2599eaa3ebd7014f60b50968b758cbd7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-co-mrk-generate-70-121054424.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-co-mrk-generate-70-121054424.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "RVMD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-21T12:10:47+00:00",
    "headline": "Broader Analyst Sentiment Bullish on Merck & Co. (MRK) Amid Tempered Short-Term Expectation and Long-Term Optimism",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is included in our list of the 10 Goldman Sachs undervalued stocks to invest in. As of January 16, 2026, analyst sentiment on Merck & Co., Inc. (NYSE:MRK) stands broadly constructive, with roughly 60% of analysts bullish. However, the $115.00 consensus price target implies a modest 3.60% upside. The broader […]",
    "url": "https://finance.yahoo.com/news/broader-analyst-sentiment-bullish-merck-121047991.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "9dca171d-161d-3d19-80c5-1313b8ad9a1f",
      "content": {
        "id": "9dca171d-161d-3d19-80c5-1313b8ad9a1f",
        "contentType": "STORY",
        "title": "Broader Analyst Sentiment Bullish on Merck & Co. (MRK) Amid Tempered Short-Term Expectation and Long-Term Optimism",
        "description": "",
        "summary": "Merck & Co., Inc. (NYSE:MRK) is included in our list of the 10 Goldman Sachs undervalued stocks to invest in. As of January 16, 2026, analyst sentiment on Merck & Co., Inc. (NYSE:MRK) stands broadly constructive, with roughly 60% of analysts bullish. However, the $115.00 consensus price target implies a modest 3.60% upside. The broader […]",
        "pubDate": "2026-01-21T12:10:47Z",
        "displayTime": "2026-01-21T12:10:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/cb218414709808bf2f63f98ca522d436",
          "originalWidth": 1280,
          "originalHeight": 853,
          "caption": "Broader Analyst Sentiment Bullish on Merck & Co. (MRK) Amid Tempered Short-Term Expectation and Long-Term Optimism",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tXp3W2zDkWcbYHYM_edP3Q--~B/aD04NTM7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/cb218414709808bf2f63f98ca522d436.cf.webp",
              "width": 1280,
              "height": 853,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BuRra1_S02PEU8kqjSl2RA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/cb218414709808bf2f63f98ca522d436.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/broader-analyst-sentiment-bullish-merck-121047991.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/broader-analyst-sentiment-bullish-merck-121047991.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-21T16:08:42+00:00",
    "headline": "Assessing Merck (MRK) Valuation After Recent Share Price Momentum And DCF Discount Signals",
    "summary": "Merck stock snapshot after recent performance Merck (MRK) has drawn fresh attention after a period where the share price and fundamentals give investors new information to weigh, with the stock last closing at $109.45. Recent returns, including about 0.6% over the past day and around 1.1% over the past week, highlight short term moves that some investors compare with the stronger month and past three months performance. See our latest analysis for Merck. Looking beyond the recent bounce,...",
    "url": "https://finance.yahoo.com/news/assessing-merck-mrk-valuation-recent-160842961.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "f7d45842-efe4-3053-ac68-2564041b4ce5",
      "content": {
        "id": "f7d45842-efe4-3053-ac68-2564041b4ce5",
        "contentType": "STORY",
        "title": "Assessing Merck (MRK) Valuation After Recent Share Price Momentum And DCF Discount Signals",
        "description": "",
        "summary": "Merck stock snapshot after recent performance Merck (MRK) has drawn fresh attention after a period where the share price and fundamentals give investors new information to weigh, with the stock last closing at $109.45. Recent returns, including about 0.6% over the past day and around 1.1% over the past week, highlight short term moves that some investors compare with the stronger month and past three months performance. See our latest analysis for Merck. Looking beyond the recent bounce,...",
        "pubDate": "2026-01-21T16:08:42Z",
        "displayTime": "2026-01-21T16:08:42Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kA84g.s9IO2ClCgTX6BCgg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DmY770n7xz5DXLM6ZHLmxA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/assessing-merck-mrk-valuation-recent-160842961.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/assessing-merck-mrk-valuation-recent-160842961.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-21T10:38:00+00:00",
    "headline": "Moderna cancer vaccine holds up; IO Biotech considers a sale",
    "summary": "Long-term data suggest Moderna’s personalized melanoma shot provides “durable tumor control,” one analyst said. Elsewhere, Insilico Medicine partnered with a startup on a popular drug target.",
    "url": "https://www.biopharmadive.com/news/moderna-melanoma-io-biotech-nlrp3-think-pfizer-novavax/809958/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "1bd5e4bc-bd74-3ffa-a2ec-96a18387beb9",
      "content": {
        "id": "1bd5e4bc-bd74-3ffa-a2ec-96a18387beb9",
        "contentType": "STORY",
        "title": "Moderna cancer vaccine holds up; IO Biotech considers a sale",
        "description": "",
        "summary": "Long-term data suggest Moderna’s personalized melanoma shot provides “durable tumor control,” one analyst said. Elsewhere, Insilico Medicine partnered with a startup on a popular drug target.",
        "pubDate": "2026-01-21T10:38:00Z",
        "displayTime": "2026-01-21T10:38:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YSECyFvzK8sIEiUW4LIicA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/heEgXBvKL8Y58FXAXGaXPg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/e36d70a3849ea73409df7aca9613c259.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/moderna-melanoma-io-biotech-nlrp3-think-pfizer-novavax/809958/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/moderna-cancer-vaccine-holds-io-103800202.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "IOBT"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "NVAX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]